Cargando…
Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome
BACKGROUND: Elevation of cardiac troponin has been documented in multiple settings without acute coronary syndrome. However, its impact on long-term cardiac outcomes in the context of acute decompensated diabetes remains to be explored. METHODS: We performed a retrospective analysis of 872 patients...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549932/ https://www.ncbi.nlm.nih.gov/pubmed/23270513 http://dx.doi.org/10.1186/1475-2840-11-154 |
_version_ | 1782256501984854016 |
---|---|
author | Eubanks, Anthony Raza, Farhan Alkhouli, Mohamad Glenn, April N Homko, Carol Kashem, Abul Bove, Alfred |
author_facet | Eubanks, Anthony Raza, Farhan Alkhouli, Mohamad Glenn, April N Homko, Carol Kashem, Abul Bove, Alfred |
author_sort | Eubanks, Anthony |
collection | PubMed |
description | BACKGROUND: Elevation of cardiac troponin has been documented in multiple settings without acute coronary syndrome. However, its impact on long-term cardiac outcomes in the context of acute decompensated diabetes remains to be explored. METHODS: We performed a retrospective analysis of 872 patients admitted to Temple University Hospital from 2004–2009 with DKA or HHS. Patients were included if they had cardiac troponin I (cTnI) measured within 24 hours of hospital admission, had no evidence of acute coronary syndrome and had a follow up period of at least 18 months. Of the 264 patients who met the criteria, we reviewed the baseline patient characteristics, admission labs, EKGs and major adverse cardiovascular events during the follow up period. Patients were categorized into two groups with normal and elevated levels of cardiac enzymes. The composite end point of the study was the occurrence of a major cardiovascular event (MACE) during the follow up period and was compared between the two groups. RESULTS: Of 264 patients, 24 patients were found to have elevated cTnI. Compared to patients with normal cardiac enzymes, there was a significant increase in incidence of MACE in patients with elevated cTnI. In a regression analysis, which included prior history of CAD, HTN and ESRD, the only variable that independently predicted MACE was an elevation in cTnI (p = 0.044). Patients with elevated CK-MB had increased lengths of hospitalization compared to the other group (p < 0.001). CONCLUSIONS: Elevated cardiac troponin I in patients admitted with decompensated diabetes and without evidence of acute coronary syndrome, strongly correlate with a later major cardiovascular event. Thus, elevated troponin I during metabolic abnormalities identify a group of patients at an increased risk for poor long-term outcomes. Whether these patients may benefit from early detection, risk stratification and preventive interventions remains to be investigated. |
format | Online Article Text |
id | pubmed-3549932 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35499322013-01-24 Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome Eubanks, Anthony Raza, Farhan Alkhouli, Mohamad Glenn, April N Homko, Carol Kashem, Abul Bove, Alfred Cardiovasc Diabetol Original Investigation BACKGROUND: Elevation of cardiac troponin has been documented in multiple settings without acute coronary syndrome. However, its impact on long-term cardiac outcomes in the context of acute decompensated diabetes remains to be explored. METHODS: We performed a retrospective analysis of 872 patients admitted to Temple University Hospital from 2004–2009 with DKA or HHS. Patients were included if they had cardiac troponin I (cTnI) measured within 24 hours of hospital admission, had no evidence of acute coronary syndrome and had a follow up period of at least 18 months. Of the 264 patients who met the criteria, we reviewed the baseline patient characteristics, admission labs, EKGs and major adverse cardiovascular events during the follow up period. Patients were categorized into two groups with normal and elevated levels of cardiac enzymes. The composite end point of the study was the occurrence of a major cardiovascular event (MACE) during the follow up period and was compared between the two groups. RESULTS: Of 264 patients, 24 patients were found to have elevated cTnI. Compared to patients with normal cardiac enzymes, there was a significant increase in incidence of MACE in patients with elevated cTnI. In a regression analysis, which included prior history of CAD, HTN and ESRD, the only variable that independently predicted MACE was an elevation in cTnI (p = 0.044). Patients with elevated CK-MB had increased lengths of hospitalization compared to the other group (p < 0.001). CONCLUSIONS: Elevated cardiac troponin I in patients admitted with decompensated diabetes and without evidence of acute coronary syndrome, strongly correlate with a later major cardiovascular event. Thus, elevated troponin I during metabolic abnormalities identify a group of patients at an increased risk for poor long-term outcomes. Whether these patients may benefit from early detection, risk stratification and preventive interventions remains to be investigated. BioMed Central 2012-12-27 /pmc/articles/PMC3549932/ /pubmed/23270513 http://dx.doi.org/10.1186/1475-2840-11-154 Text en Copyright ©2012 Eubanks et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Investigation Eubanks, Anthony Raza, Farhan Alkhouli, Mohamad Glenn, April N Homko, Carol Kashem, Abul Bove, Alfred Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome |
title | Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome |
title_full | Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome |
title_fullStr | Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome |
title_full_unstemmed | Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome |
title_short | Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome |
title_sort | clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549932/ https://www.ncbi.nlm.nih.gov/pubmed/23270513 http://dx.doi.org/10.1186/1475-2840-11-154 |
work_keys_str_mv | AT eubanksanthony clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome AT razafarhan clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome AT alkhoulimohamad clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome AT glennapriln clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome AT homkocarol clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome AT kashemabul clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome AT bovealfred clinicalsignificanceoftroponinelevationsinacutedecompensateddiabeteswithoutclinicalacutecoronarysyndrome |